Lisa Rafkin

2.0k total citations
18 papers, 605 citations indexed

About

Lisa Rafkin is a scholar working on Endocrinology, Diabetes and Metabolism, Genetics and Surgery. According to data from OpenAlex, Lisa Rafkin has authored 18 papers receiving a total of 605 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Endocrinology, Diabetes and Metabolism, 18 papers in Genetics and 17 papers in Surgery. Recurrent topics in Lisa Rafkin's work include Diabetes and associated disorders (18 papers), Pancreatic function and diabetes (17 papers) and Diabetes Management and Research (17 papers). Lisa Rafkin is often cited by papers focused on Diabetes and associated disorders (18 papers), Pancreatic function and diabetes (17 papers) and Diabetes Management and Research (17 papers). Lisa Rafkin collaborates with scholars based in United States, Canada and United Kingdom. Lisa Rafkin's co-authors include Jay S. Skyler, Jerry P. Palmer, Jay M. Sosenko, Carla J. Greenbaum, Jeffrey P. Krischer, Jeffrey L. Mahon, Craig A. Beam, David Boulware, Della Matheson and Kevan C. Herold and has published in prestigious journals such as Diabetes Care, Diabetes and Diabetic Medicine.

In The Last Decade

Lisa Rafkin

18 papers receiving 594 citations

Peers

Lisa Rafkin
E. Sabbah Finland
E. Bakhtadze Sweden
Katelijn Decochez Belgium
Taylor M. Triolo United States
Maria Luisa Arpi Italy
Anna E. Long United Kingdom
J. M. McNally United Kingdom
Patrick Goubert Belgium
Patrick Rowe United States
DA Heaton United Kingdom
E. Sabbah Finland
Lisa Rafkin
Citations per year, relative to Lisa Rafkin Lisa Rafkin (= 1×) peers E. Sabbah

Countries citing papers authored by Lisa Rafkin

Since Specialization
Citations

This map shows the geographic impact of Lisa Rafkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Rafkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Rafkin more than expected).

Fields of papers citing papers by Lisa Rafkin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Rafkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Rafkin. The network helps show where Lisa Rafkin may publish in the future.

Co-authorship network of co-authors of Lisa Rafkin

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Rafkin. A scholar is included among the top collaborators of Lisa Rafkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Rafkin. Lisa Rafkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
Sims, Emily K., Susan Geyer, Suzanne Bennett Johnson, et al.. (2019). Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet’s Pathway to Prevention. Diabetes Care. 42(12). 2228–2236. 24 indexed citations
3.
Ismail, Heba M., Carmella Evans‐Molina, Linda A. DiMeglio, et al.. (2019). Associations of HbA1c with the timing of C‐peptide responses during the oral glucose tolerance test at the diagnosis of type 1 diabetes. Pediatric Diabetes. 20(4). 408–413. 5 indexed citations
4.
Baidal, David A., Janine Sanchez, Rodolfo Alejandro, et al.. (2018). POSEIDON study: a pilot, safety and feasibility trial of high-dose omega3 fatty acids and high-dose cholecalciferol supplementation in type 1 diabetes.. PubMed. 6(1). 6 indexed citations
5.
Bingley, Polly J., et al.. (2018). Type 1 Diabetes TrialNet: A Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 Diabetes. Diabetes Care. 41(4). 653–661. 47 indexed citations
6.
Sosenko, Jay M., Susan Geyer, Jay S. Skyler, et al.. (2017). The influence of body mass index and age on C‐peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial‐type 1. Pediatric Diabetes. 19(3). 403–409. 22 indexed citations
7.
Liu, YF, Lisa Rafkin, Della Matheson, et al.. (2017). Use of self‐collected capillary blood samples for islet autoantibody screening in relatives: a feasibility and acceptability study. Diabetic Medicine. 34(7). 934–937. 19 indexed citations
8.
Bingley, Polly J., Lisa Rafkin, Della Matheson, et al.. (2015). Use of Dried Capillary Blood Sampling for Islet Autoantibody Screening in Relatives: A Feasibility Study. Diabetes Technology & Therapeutics. 17(12). 867–871. 16 indexed citations
9.
Sosenko, Jay M., Jay S. Skyler, Craig A. Beam, et al.. (2015). The Development and Utility of a Novel Scale That Quantifies the Glycemic Progression Toward Type 1 Diabetes Over 6 Months. Diabetes Care. 38(5). 940–942. 13 indexed citations
10.
Sosenko, Jay M., Jay S. Skyler, Linda A. DiMeglio, et al.. (2014). A New Approach for Diagnosing Type 1 Diabetes in Autoantibody-Positive Individuals Based on Prediction and Natural History. Diabetes Care. 38(2). 271–276. 64 indexed citations
11.
Sosenko, Jay M., Jay S. Skyler, Jeffrey L. Mahon, et al.. (2014). Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Improving the Accuracy of the Risk Classification of Type 1 Diabetes. Diabetes Care. 37(4). 979–984. 46 indexed citations
12.
Sosenko, Jay M., Jay S. Skyler, Craig A. Beam, et al.. (2013). Acceleration of the Loss of the First-Phase Insulin Response During the Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants. Diabetes. 62(12). 4179–4183. 67 indexed citations
13.
Sosenko, Jay M., Jay S. Skyler, Jerry P. Palmer, et al.. (2013). The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and Their Incorporation Into an Autoantibody Risk Score in Relatives of Type 1 Diabetic Patients. Diabetes Care. 36(9). 2615–2620. 77 indexed citations
14.
Sosenko, Jay M., Jay S. Skyler, Jeffrey L. Mahon, et al.. (2012). The Application of the Diabetes Prevention Trial–Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes. Diabetes Care. 35(7). 1552–1555. 33 indexed citations
15.
Sosenko, Jay M., Jay S. Skyler, Jeffrey L. Mahon, et al.. (2011). Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care. 34(8). 1785–1787. 44 indexed citations
16.
Sosenko, Jay M., Jeffrey L. Mahon, Lisa Rafkin, et al.. (2010). A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants. Pediatric Diabetes. 12(2). 85–90. 12 indexed citations
17.
Sosenko, Jay M., Jay S. Skyler, Jeffrey P. Krischer, et al.. (2010). Glucose Excursions Between States of Glycemia With Progression to Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1). Diabetes. 59(10). 2386–2389. 31 indexed citations
18.
Sosenko, Jay M., Jerry P. Palmer, Lisa Rafkin, et al.. (2009). Trends of Earlier and Later Responses of C-peptide to Oral Glucose Challenges With Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants. Diabetes Care. 33(3). 620–625. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E. Sabbah Breakdown of academic impact, for papers by E. Bakhtadze Breakdown of academic impact, for papers by Katelijn Decochez Breakdown of academic impact, for papers by Taylor M. Triolo Breakdown of academic impact, for papers by Maria Luisa Arpi Breakdown of academic impact, for papers by Anna E. Long Breakdown of academic impact, for papers by J. M. McNally Breakdown of academic impact, for papers by Patrick Goubert Breakdown of academic impact, for papers by Patrick Rowe Breakdown of academic impact, for papers by DA Heaton
Rankless by CCL
2026